Needham Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $105

Needham analyst Joseph Stringer has maintained a Buy rating on Ionis Pharmaceuticals (NASDAQ: IONS) and increased the price target from $103 to $105. This adjustment reflects the analyst's positive outlook on the company's performance.